Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
8.869 CHF
711.47 M CHF
3.08 B CHF
81.07 M
About IDEXX Laboratories, Inc.
Sector
Industry
CEO
Jonathan J. Mazelsky
Website
Headquarters
Westbrook
Founded
1983
FIGI
BBG00LVDKYW8
IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.
Resistance Analysis in Bottoming Stocks: IDXX, OKTAResistance Analysis in Bottoming Stocks: Looking Ahead to Q1 2023 Earnings
Stocks that are slowly crawling their way out of the correction of 2022 are now moving up to challenge the more difficult resistance levels from the intermediate-term downtrend. These resistance levels are sideways trends
$IDXX with a bullish outlook following its earnings #StocksThe PEAD projected a bullish outlook for $IDXX after a positive under reaction following its earnings release placing the stock in drift A with an expected accuracy of 42.68%.
IDXX$IDXX - weekly vs. monthly
Weekly (left) - new swing high + MACD crossing above zero line + RSI rising & above 50
Monthly (right) – bullish candle developing off the month 50-day EMA. RSI double bottomed at RSI 38.2 level plus crossed above 50; MACD looks to be crossing after being in a decline si
IDXX - broke out of consolidationIDXX had a strong move last Friday on high volume that brought it to the top of it's 2 months consolidation range high of 447.80. The following Monday (9 Jan),it formed a little Doji Candle just slightly above this level , perhaps traders were still skeptical if this break was for real. The day aft
$IDXX with a Bullish outlook following its earnings #Stocks The PEAD projected a Bullish outlook for $IDXX after a Positive over reaction following its earnings release placing the stock in drift B with an expected accuracy of 75%.
$IDXX with a Neutral outlook following its earnings #Stocks The PEAD projected a Neutral outlook for $IDXX after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 66.67%.
Ugly TopPrice is below the neckline.
Short is 2.18%.
Possible W pattern forming.
This could go up a bit before going down again.
No recommendation.
Earnings 8-3 BMO
IDXX - Megaphone ContinuationAn idea for IDXX supporting the continuation of a strong trend line in solid white
If this trend line does not hodl then the level in green is a good potential spot for price recovery
Daily timeframe
$IDXX with a Neutral outlook following its earnings #Stocks The PEAD projected a Neutral outlook for $IDXX after a Negative over reaction following its earnings release placing the stock in drift C with an expected accuracy of 60%.
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of IX1 is 384.781 CHF — it has increased by 0.48% in the past 24 hours. Watch IDEXX LABORATORIES stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BX exchange IDEXX LABORATORIES stocks are traded under the ticker IX1.
We've gathered analysts' opinions on IDEXX LABORATORIES future price: according to them, IX1 price has a max estimate of 499.89 CHF and a min estimate of 384.19 CHF. Watch IX1 chart and read a more detailed IDEXX LABORATORIES stock forecast: see what analysts think of IDEXX LABORATORIES and suggest that you do with its stocks.
IX1 stock is 0.48% volatile and has beta coefficient of 1.26. Track IDEXX LABORATORIES stock price on the chart and check out the list of the most volatile stocks — is IDEXX LABORATORIES there?
Today IDEXX LABORATORIES has the market capitalization of 30.70 B, it has decreased by −1.93% over the last week.
Yes, you can track IDEXX LABORATORIES financials in yearly and quarterly reports right on TradingView.
IDEXX LABORATORIES is going to release the next earnings report on Feb 10, 2025. Keep track of upcoming events with our Earnings Calendar.
IX1 earnings for the last quarter are 2.37 CHF per share, whereas the estimation was 2.27 CHF resulting in a 4.46% surprise. The estimated earnings for the next quarter are 2.17 CHF per share. See more details about IDEXX LABORATORIES earnings.
IDEXX LABORATORIES revenue for the last quarter amounts to 826.70 M CHF, despite the estimated figure of 830.75 M CHF. In the next quarter, revenue is expected to reach 844.87 M CHF.
IX1 net income for the last quarter is 197.32 M CHF, while the quarter before that showed 182.77 M CHF of net income which accounts for 7.96% change. Track more IDEXX LABORATORIES financial stats to get the full picture.
No, IX1 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 11.00 K employees. See our rating of the largest employees — is IDEXX LABORATORIES on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. IDEXX LABORATORIES EBITDA is 1.05 B CHF, and current EBITDA margin is 32.98%. See more stats in IDEXX LABORATORIES financial statements.
Like other stocks, IX1 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade IDEXX LABORATORIES stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So IDEXX LABORATORIES technincal analysis shows the neutral today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating IDEXX LABORATORIES stock shows the strong sell signal. See more of IDEXX LABORATORIES technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.